Background: The forced expiratory volume at first second (FEV 1 ) during spirometry reflects the severity of chronic obstructive pulmonary disease (COPD) and is known to be an important prognostic factor. It is uncertain whether the response to short-acting bronchodilators may predict long-term outcomes such as hospitalizations and mortality. Methods: We retrospectively studied a total of 1203 consecutive COPD patients without significant comorbidities during a mean (AESD) of 69 AE 39 months of follow-up. At baseline the subjects were classified as those with positive or negative bronchodilator test (BDT) and also in quartiles of absolute bronchodilator response to 400 mg of salbutamol. Hospital visits and mortality were the end points. Results: A positive bronchodilator test was observed in 332 (27.6%) of the patients. There were 73 (21.9%) deaths in patients with a positive BDT versus 253 (28.7%) in those with a negative BDT (p Z 0.04). In adjusted Cox regression analysis a positive BDT was significantly associated with a prolonged time to first hospitalization. After stratifying the population by quartiles of response to BDT, a doseeresponse relationship was observed with the best outcomes in the quartile with highest level of airflow reversibility, even after controlling for age, sex, BMI, smoking status and baseline postbronchodilator FEV 1 . Conclusions: In a large population of well characterized COPD patients without significant comorbidities, those demonstrating higher levels of reversibility at baseline presented better long-term outcomes even after controlling for other known prognostic factors. ª
Introduction
In Spain, up to 10.2% of the adult population is affected by chronic obstructive pulmonary disease (COPD) [1] . This chronic and debilitating disease is associated with an impairment in quality of life and a reduction of survival [2] . Several prospective studies have attempted to identify factors associated with poor outcomes such as hospitalizations and/or mortality [3e8], including multidimensional indices [9, 10] .
Acute bronchial reversibility after inhalation of a shortacting beta-2 agonist has been traditionally used to differentiate asthma from COPD. However, it is clear that a positive reversibility test does not exclude the diagnosis of COPD [11] . In the ECLIPSE cohort, 24% of patients with COPD met the criteria for reversibility [12] , although bronchodilator status (positive or negative) varied temporally and did not differentiate clinically relevant outcomes [12, 13] . Given the arbitrary nature of the established thresholds, the changes in positive or negative status may represent small increases or decreases in reversibility that move individual patients from one side to the other of the threshold; i.e. from 11.8% to 12.2% increase in FEV 1 or viceversa, which in reality may not represent clinically meaningful changes in reversibility [14] .
To investigate the impact of reversibility on long-term outcomes, we followed a cohort of well characterized COPD patients and analyzed the outcomes according to the result of the bronchodilator test. We also extended the analysis by dividing the population into quartiles of bronchodilator response to investigate a possible doseeresponse effect of reversibility on hospitalizations and mortality.
Method
We retrospectively identified all consecutive newly referred patients from January 1st, 1996 to November 30th, 2008, for pulmonary function evaluation to the Hospital Universitario Miguel Servet (Zaragoza, Spain). Eligible patients were those with diagnosed COPD defined by a history of current or ex-smokers of at least 20 pack-years and a post-bronchodilator FEV 1 /FVC < 0.7. Patients with history of malignancy at baseline or history of asthma, those with any comorbidity included in the Charlson index [15] and those who were unable to perform the required tests were excluded. We also excluded nonresidents in the region due to the difficulties in follow-up. The study was approved by the research review board of the Hospital Universitario Miguel Servet (Zaragoza, Spain).
Measurements
Baseline variables were systematically recorded at the pulmonary function laboratory using a standardized protocol. The ATS-DLD-78 adult questionnaire [16] was administered before the PFTs. Dyspnea was assessed using the modified Medical Research Questionnaire dyspnea scale [17] . The pulmonary function tests (PFTs) were performed according to the guidelines of the American Thoracic Society (ATS) [18] when patients had been in stable condition for at least 6 weeks. Spirometric reference values were those of the European Community for Coal and Steel (ECCS) [19] . Bronchodilator treatment was withdrawn prior to the PFTs according to standard practice. A qualified pulmonary technologist conducted maximal in-and expiratory flow volume curves with subjects seated before and after administration of 400 mg salbutamol via a metered dose inhaler with a large volume spacer. The "best curve" was selected from the largest sum of FEV 1 and forced vital capacity (FVC). Bronchodilator responsiveness (BDR) was calculated according to ATS guidelines [18] . A FEV 1 change from initial less than 12% and FEV 1 absolute change less than 200 mL was considered as a negative BDR.
Follow-up
Patients attended the pulmonary clinics at least once a year or until death and the history of exacerbations of COPD and hospitalizations was obtained at each visit. The end points of this study were: 1) first severe COPD exacerbation, defined as an exacerbation of COPD requiring an emergency room visit and or hospitalization, 2) all cause hospitalization, 3) death by all causes and death due to COPD and 4) first respiratory event, including emergency room visit or hospitalization for an exacerbation or respiratory death. The occurrence of each endpoint was thoroughly assessed by reviewing medical records and computerized databases, and when necessary by contacting the primary care physician and/or the pulmonologist in charge of the patient.
Statistical analysis
Categorical variables were compared with the Chi-square test or Fisher's exact test when appropriate. Continuous variables were compared using the Student's t-test or the one way analysis of variance (ANOVA) where appropriate. The rates of emergency visits and hospitalizations were calculated as the number of episodes divided by the years of follow-up. All post-hoc comparisons were made with the Bonferroni correction for multiple comparisons.
The time to each of the end points was compared among the different groups by means of Cox regression model adjusted by the following variables: age, sex, BMI, smoking status and postbronchodilator FEV 1 (% predicted). Data were processed with the SPSS 17.0. The level of significance was set at 0.05 (two-tailed).
Results
During the period of the study 7894 individuals were referred for PFTs, of which 3013 (38.1%) were diagnosed with COPD. Of these, 1203 fulfilled the inclusion criteria and were included in the study (Figure 1 ). At baseline the mean age was 63 years (SD Z 9.1 years), 93.4% were men and the mean prebronchodilator FEV 1 was 57.5% predicted (SD Z 20.1%). A positive bronchodilator test (BDTþ) was observed in 332 (27.6%). Patients with a BDTþ were more frequently men and had significantly reduced values of all spirometric parameter prebronchodilator. However, there were no significant differences in all postbronchodilator spirometric parameters between patients with positive or negative BDT (Table 1) . No differences were observed in patterns of pharmacologic treatment either at entry in the cohort or at the end of follow-up (Table 1) .
Hospital visits and mortality according to results of BDT
The mean follow-up time was 69.1 months, being significantly longer for the group with BDT þ (75.2 (SD Z 39.6) months vs. 66.9 (SD Z 39.3); p Z 0.002). The rate of hospitalization for COPD was significantly lower for BDTþ patients and the time to the first hospitalization was significantly prolonged (39.3 months (SD Z 31.5) vs. 32.4 months (SD Z 30.2); p Z 0.028) ( Table 2) . Hospitalization rates for other causes did not differ between groups, but the time to the first hospitalization was significantly longer in PBD þ patients (37 months (SD Z 31.7) vs 30.6 months (SD Z 29.4); p Z 0.024). The time to the first respiratory event was also significantly prolonged for BDT þ patients (29 months (SD Z 27.8) vs. 24.3 months (SD Z 25.6); p Z 0.009) ( Table 2 ).
All-cause mortality was significantly reduced in BDT þ patients (21.9% vs. 28.7%; p Z 0.04). However, the reduction in mortality for COPD in BDTþ patients just failed to reach statistical significance (10.5% vs. 17%; p Z 0.072) ( Table 2 ).
Time to hospitalization and death according to BDT
The results of the adjusted Cox regression model for time to the first hospitalization according to BDT results are shown in Table 3 and Figure 2 (a). Together with a BDT-, the only variables significantly associated with a shorter time to first hospitalization were the older age group (>65 years), low BMI and low postbronchodilator FEV 1 (%).
A BDT-was associated with a significantly shorter time to first respiratory event together with age >65, female sex, low BMI, and lower post-bronchodilator FEV 1 (%) ( Table 3 and Figure 2 
Hospital visits and mortality according to bronchodilator response in quartiles
The most reversible group (Q4) included significantly more men and the prebronchodilator FEV 1 (%) was lower (Table 4) . Patients in the Q4 had better outcomes during follow-up compared with the remaining groups ( Table 5 ). The hospitalization rate for Q4 was 0.6 event per year (SD Z 1.5) compared with 1 (SD from 1.9 to 2.8) for the rest of patients (p Z 0.025). Time to hospitalization for all causes was significantly prolonged for Q4 (p Z 0.015). All cause mortality was significantly reduced for Q4 (20.5% compared with 28.4%, 30.4% and 29.2% for Q1, Q2 and Q3, respectively; p Z 0.025), but mortality by COPD was not significant (p Z 0.093).
Time to hospitalization and death according to bronchodilator response in quartiles
Patients in Q4 had a significantly prolonged time to the first hospitalization compared with the remaining quartiles, after adjusting for the remaining variables. Older age, low BMI and a lower postbronchodilator FEV 1 (%) were also significantly associated with reduced time to the first hospitalization (Table 6 and Figure 3 (a)). Similarly, patients in Q4 had a prolonged time to the first respiratory event after adjustment (Table 6 and Figure 3(b) ). Older age, low BMI and lower postbronchodilator FEV 1 (%) were also significantly associated with reduced time to the first respiratory event. In this case female gender was also significantly associated with a shorter time to the event (Table 6 ).
Discussion
The results of the current study show that patients with a positive BDT have a better prognosis demonstrated by a significantly reduced hospitalization rate for COPD and a reduced all-cause mortality, with an almost statistically significant reduction in mortality for COPD. These patients also had a significantly prolonged time to the first respiratory event (either death, hospitalization or emergency room visit for an exacerbation). These differences persisted after adjusting by age, postbronchodilator FEV 1 and smoking habits. Furthermore, by dividing the population into quartiles of bronchodilator response, we verified that there is a doseeresponse relationship in most long-term outcomes evaluated, being better in patients with a more reversible BDT. Our series is unique because the selection criteria allowed analysis of the influence of reversibility on outcomes without the confounding factor of severe comorbidities.
It has been repeatedly demonstrated that bronchodilator reversibility status varies temporally and, therefore, classifying COPD patients into positive or negative BDT does not have prognostic implications and does not help in therapeutic decisions [12, 13] . The problem stems in the dichotomization of a continuous variable; the reversibility of most COPD patients is close to the threshold of what is considered a positive (reversible) BDT [13, 20] . Therefore, small random changes in reversibility (or just the normal variability of the measurement) may lead a subject to switch sides of the arbitrary threshold. These changes in reversibility status (from positive to negative or viceversa) may not relate to differences in clinical, physiological or phenotypic characteristics. To really address the issue of the importance of variability in reversibility, it is better to determine the magnitude of the difference in bronchodilator response between measurements for each individual over time rather than the changes defined as positive or negative status, and relates the magnitude of change to differences in clinical outcomes of importance. This is highlighted by the results of the Lung Health Study which demonstrated that after the first year of follow-up there was no change in absolute bronchodilator response in mild COPD patients who were sustained quitters [21] , supporting the idea of some stability in bronchodilator response, at least when the influence of changes in smoking status is avoided. In further supporting the view of bronchodilator response as a continuous measurement, our results suggest that there is a continuum in the long-term outcomes according to the intensity of the response, with the best outcomes observed in patients with the highest reversibility. Interestingly, the magnitude of reversibility was far from the currently accepted threshold of 200 mL and 12% increase in FEV 1 . In fact, patients in the highest quartile of reversibility, who showed the best outcomes, had a mean FEV 1 reversibility of 333 mL or 23.7%.
It could be argued that the better outcomes in this more reversible quartile could be due to the inclusion of asthmatics. However, we excluded all patients with a previous diagnosis of asthma and the demographic and clinical characteristics of patients in this quartile were similar to the rest of the population, with a mean age of 62.1 years and all of smokers or ex-smokers with a mean smoking consumption of 50 pack-years, clearly fulfilling the established criteria of COPD. In a previous study, Hansen et al. [22] followed a cohort of 1586 subjects and, in agreement with our results, they found that after controlling for baseline FEV 1 , bronchodilator reversibility was associated with better survival. In contrast, after controlling for the best FEV 1 , reversibility became non-significant and non-predictive. This study was different from ours in that these authors included patients with asthma and COPD and did not exclude comorbidities. In fact, we observed that bronchodilator response was still predictive for time to first hospitalization and time to first respiratory event even after controlling for postbronchodilator FEV 1 , and this effect was mainly present in those subjects in the most reversible quartile. Our results also support those studies that have shown that postbronchodilator FEV 1 is a significant and independent prognostic factor for long-term outcomes [23, 24] and differs from the Lung Health Study analysis [24] where Mannino et al. found a similar degree of accuracy in the prediction of mortality for pre-and postbronchodilator FEV 1 . The difference may relate to the different severity of airflow obstruction between the populations included in these studies. In any case, the analysis of the Lung Health Study data did not evaluate the additive prognostic information of reversibility in the prediction of mortality [24] . Our results concur with those observed in the ULIFT trial in which a significantly lower mortality was observed in patients with a BDT þ according to the same criteria used in our study, both in the tiotropium arm (208/1357 (15.3%) for non-responders to short-acting bronchodilators versus 152/ 1520 (10%) for responders; OR: 1.63, 95%CI: 1.30e2.07) and in the placebo arm (225/1393 (16.2%) for non-responders versus 164/1513 (10.8%) for responders; OR: 1.58, 95%CI: 1.27e1.97) [25] , supporting the concept of better long term prognosis for reversible patients.
The usefulness of acute reversibility to short-acting bronchodilators in predicting response to pharmacological treatment has been questioned [26] . In fact, most studies suggest that a lack of acute response to short-acting bronchodilators does not preclude a beneficial long-term response to maintenance bronchodilator treatment [25, 27] . However, increased reversibility to short-acting beta-2 agonists has been associated with a different pattern of bronchial inflammation with an increase in eosinophils and in exhaled nitric oxide (NO) [28] . As a consequence, reversible COPD patients have demonstrated an increased response to inhaled corticosteroids compared with irreversible patients [14,29e33] . This differential response to inhaled corticosteroids could justify a more personalized approach to treatment based on a distinct clinical phenotype [34, 35] .
Our study has some limitations. Restricting the analysis to patients without comorbidities may provide a better understanding of the role of reversibility in prognosis without interference of comorbid diseases; however, these results may not be extrapolated to patients with severe comorbidities. We did not analyze the response in lung volumes after BDT. This may be particularly important in severe cases in which improvements in FVC may be more frequent than improvements in FEV 1 [36, 37] , but only 4.7% of our cases had an FEV 1 < 30% predicted. Some characteristics that may influence outcomes were not systematically collected at the time of the design of the study, such as exercise capacity or degree of dyspnea. In contrast, the study has several strengths; patients were recruited from a pulmonary function laboratory in an experienced teaching hospital reassuring the quality and uniformity of spirometries and BDTs performed. Follow-up was centralized with a dedicated group of investigators and the aid of health registries to detect unreported hospital visits and deaths.
In summary, the present results have shown that the increased reversibility to short-acting beta-2 agonist is associated with better long-term outcomes in COPD patients. This association displays a doseeresponse relationship, with the better outcomes observed in those in the forth quartile of reversibility, which indicates that the classification of subjects into positive or negative BDT according to an arbitrary threshold should be restricted to epidemiological studies, but may be misleading from a clinical point of view.
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